A. J. Wilcox, C. R. Weinberg, O. Connor, and J. F. , Incidence of early loss of pregnancy, N Engl J Med, vol.319, pp.189-94, 1988.

S. Hernandez-diaz, S. Toh, and S. Cnattingius, Risk of preeclampsia in first and subsequent pregnancies: prospective cohort study, BMJ, vol.338, 2009.

R. J. Levine, S. E. Maynard, and C. Qian, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, vol.350, pp.672-83, 2004.

A. Ahmed and M. J. Cudmore, Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?, Biochem Soc Trans, vol.37, pp.1237-1279, 2009.

A. Ahmed, New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications, Thromb Res, vol.127, issue.3, pp.72-77, 2011.

A. M. Cumming, R. C. Tait, and S. Fildes, Development of resistance to activated protein C during pregnancy, Br J Haematol, vol.90, pp.725-732, 1995.

P. Clark, J. Brennand, and J. A. Conkie, Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy, Thromb Haemost, vol.79, pp.1166-70, 1998.

G. Sarig, A. J. Klil-drori, and D. Chap-marshak, Activation of coagulation in amniotic fluid during normal human pregnancy, Thromb Res, vol.128, pp.490-495, 2011.

O. Erez, R. Romero, and D. Hoppensteadt, Tissue factor and its natural inhibitor in pre-eclampsia and SGA, J Matern Fetal Neonatal Med, vol.21, pp.855-69, 2008.

P. Clark, I. D. Walker, and I. Greer, Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight, Lancet, vol.353, pp.292-295, 1999.

P. Redecha, R. Tilley, and M. Tencati, Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury, Blood, vol.110, pp.2423-2454, 2007.

T. E. Dudding and J. Attia, The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis, Thromb Haemost, vol.91, pp.700-711, 2004.

L. Robertson, O. Wu, and P. Langhorne, Thrombophilia in pregnancy: a systematic review, Br J Haematol, vol.132, pp.171-96, 2006.

M. A. Rodger, M. T. Betancourt, and P. Clark, The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies, PLoS Med, vol.7, 2010.

N. Zdoukopoulos and E. Zintzaras, Genetic risk factors for placental abruption: a HuGE review and metaanalysis, Epidemiology, vol.19, pp.309-332, 2008.

M. A. Rodger, M. C. Walker, and G. N. Smith, Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study, J Thromb Haemost, vol.12, pp.469-78, 2014.

R. Sood, S. Kalloway, and A. E. Mast, Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells, Blood, vol.107, pp.3173-80, 2006.

A. Aharon, B. Brenner, and T. Katz, Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis, Thromb Haemost, vol.92, pp.776-86, 2004.

B. Huppertz, M. Kadyrov, and J. C. Kingdom, Apoptosis and its role in the trophoblast, Am J Obstet Gynecol, vol.195, pp.29-39, 2006.

A. Aharon, N. Lanir, A. Drugan, and B. Brenner, Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment, J Thromb Haemost, vol.3, pp.2355-2362, 2005.

E. Shomer, S. Katzenell, and Y. Zipori, Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function, Hypertension, vol.62, pp.893-901, 2013.

A. Aharon, S. Katzenell, T. Tamari, and B. Brenner, Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications, J Thromb Haemost, vol.7, pp.1047-50, 2009.

S. J. Germain, G. P. Sacks, and S. R. Sooranna, Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles, J Immunol, vol.178, pp.5949-56, 2007.

I. A. Greer and C. Nelson-piercy, Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy, Blood, vol.106, pp.401-408, 2005.

J. C. Gris, E. Mercier, and I. Quere, Low-molecularweight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder, Blood, vol.103, pp.3695-3704, 2004.

B. Brenner, R. Hoffman, and H. Carp, Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study, J Thromb Haemost, vol.3, pp.227-236, 2005.

M. Dolitzky, A. Inbal, and Y. Segal, A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages, Fertil Steril, vol.86, pp.362-368, 2006.

P. Clark, I. D. Walker, and P. Langhorne, SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecularweight heparin and low-dose aspirin in women with recurrent miscarriage, Blood, vol.115, pp.4162-4169, 2010.

S. P. Kaandorp, M. Goddijn, and J. A. Van-der-post, Aspirin plus heparin or aspirin alone in women with recurrent miscarriage, N Engl J Med, vol.362, pp.1586-96, 2010.

E. Rey, P. Garneau, and M. David, Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial, J Thromb Haemost, vol.7, pp.58-64, 2009.

J. C. Gris, C. Chauleur, and J. L. Faillie, Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial, Thromb Haemost, vol.104, pp.771-780, 2010.

I. Martinelli, P. Ruggenenti, and I. Cetin, Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial, Blood, vol.119, pp.3269-75, 2012.

J. C. Gris, S. Bouvier, and N. Molinari, Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study, Blood, vol.119, pp.2624-2656, 2012.

J. I. De-vries, M. G. Van-pampus, and W. M. Hague, Lowmolecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUITRCT, J Thromb Haemost, vol.10, pp.64-72, 2012.

J. M. Dodd, A. Mcleod, R. C. Windrim, and J. Kingdom, Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction, Cochrane Database Syst Rev, vol.7, p.6780, 2013.

M. A. Rodger, M. Carrier, L. Gal, and G. , Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications, Blood, vol.123, pp.822-830, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935578

M. A. Rodger, W. M. Hague, and J. Kingdom, Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial, Lancet, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01258557